(KZR) – Management Comments
-
Kezar Life Sciences (KZR) Granted Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis & Dermatomyositis
-
Kezar Life Sciences (KZR) Provides Data Update from MISSION Study of KZR-616 in Patients with SLE
Back to KZR Stock Lookup